Solid Tumor Clinical Trial
Official title:
A Single-center, Randomized, Open-label Pharmacokinetic Study of Famitinib Malate Capsules in Healthy Subjects
Verified date | June 2023 |
Source | Jiangsu HengRui Medicine Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.
Status | Completed |
Enrollment | 70 |
Est. completion date | November 22, 2021 |
Est. primary completion date | October 8, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Gender: healthy male and female subjects. 2. Age: 18 years old and above (including 18 years old). 3. Weight: male subjects should not be less than 50.0kg, female subjects should not be less than 45.0kg, body mass index [BMI=weight (kg)/height2 (m2)] is 19.0 to 26.0kg/m2 (including boundary values). 4. Subjects with fertility and their partners have no fertility plan and voluntarily take medically approved high-efficiency contraception methods (see appendix 1 for details), and no plan to donate eggs or sperm within 28 weeks after signing the informed consent. Women with childbearing potential must have a negative serum pregnancy test within 24 hours before taking the study drug for the first time. 5. Subjects must give informed consent to this study before the experiment, and voluntarily sign a written informed consent form. 6. The subject can communicate well with the researcher and can complete the research in accordance with the research regulations. Exclusion Criteria: 1. Those who are allergic to the active ingredients of the preparation and related compounds and any excipients or are allergic to two or more drugs (or food). 2. Those who cannot follow a unified diet (such as intolerance to standard meals, etc.). 3. Those who cannot tolerate venepuncture, and those who have a history of fainting needles and bleeding. 4. There is a history of cardiovascular (such as hypertension), liver, kidney (such as chronic kidney disease), endocrine, blood system, respiratory system, malignant tumour, mental abnormality, severe infection, etc. or the existing above diseases that the researcher judges to be clinically significant. 5. Chronic or active gastrointestinal diseases such as esophagitis, gastritis, gastric ulcer, enteritis, gastrointestinal bleeding, gastroesophageal reflux disease, gastrointestinal obstruction, oesophageal varices, or gastrointestinal surgery (part of the digestive tract resection, cholecystectomy), etc., and the investigator believes that there is still clinical significance. 6. During the screening period, there are serious gastrointestinal symptoms (such as nausea, vomiting, stomach pain, abdominal pain, diarrheal, abdominal discomfort, abdominal distension, etc.), and the investigator believes that it is currently clinically meaningful. 7. Patients with upper respiratory tract infection during the screening period, and the investigator believes that it is currently clinically significant. 8. Those who have undergone major surgery within 6 months before screening, or who plan to undergo surgery during the study period, and those who have undergone surgery that will affect drug absorption, distribution, metabolism, and excretion (except for appendicitis surgery). 9. During the screening period, physical examination, vital signs, 12-lead electrocardiogram, chest radiograph, abdominal ultrasound, blood routine, blood biochemistry, urine routine, blood coagulation and thyroid function (FT3, FT4, TSH) abnormalities, the investigator judged that the abnormalities have clinical significance. 10. Abnormal test results of hepatitis B surface antigen, hepatitis C virus antibody, Treponema pallidum antibody or human immunodeficiency virus antibody have clinical significance. 11. Those who drank excessive amounts of tea, coffee, or caffeinated beverages (more than 8 cups a day, 1 cup = 200 mL) within 3 months before screening; or consumed any food or beverages containing caffeine within 48 hours before the first administration of the study drug (Such as coffee, strong tea, chocolate, etc.). 12. Those who have consumed any beverages or foods that are rich in xanthine or grapefruit ingredients or other beverages or foods that affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours before the first administration of the study drug. 13. Any drug that interacts with this drug has been used within 4 weeks before screening (see appendix 3). 14. Those who have used long-acting estrogen or progestin injections or implants within 6 months before the test; those who have used short-acting contraceptives within 30 days before the test. 15. Those who have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines, or health care products in the 14 days before the first administration of the study drug. |
Country | Name | City | State |
---|---|---|---|
China | Xiangya Hospital Central South University | Changsha | Hunan |
Lead Sponsor | Collaborator |
---|---|
Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum observed plasma concentration (Cmax) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Area under the plasma concentration versus time curve (AUC0-t) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Area under the plasma concentration versus time curve (AUC0-8) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Time to maximum observed plasma concentration (Tmax) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Elimination half-life (T1/2) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Apparent oral clearance (CL/F) for Famitinib after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Apparent Volume of Distribution (Vz/F) Famitinib after Single dose | from Day1 to Day9 after the first dose | ||
Primary | Maximum observed plasma concentration (Cmax) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Area under the plasma concentration versus time curve (AUC0-t) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Area under the plasma concentration versus time curve (AUC0-8) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Time to maximum observed plasma concentration (Tmax) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Time to elimination half-life (T1/2) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Apparent oral clearance (CL/F) for SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Primary | Apparent Volume of Distribution (Vz/F) SHR116637 after Single dose | from Day 1 to Day 9 after the first dose | ||
Secondary | Number of subjects with adverse events and severity of adverse events | from Day 1 to Day 16 after the first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
Recruiting |
NCT05580991 -
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02846038 -
Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
|
||
Recruiting |
NCT05159388 -
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Recruiting |
NCT05981703 -
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06014502 -
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04107311 -
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
|
||
Active, not recruiting |
NCT04078152 -
Durvalumab Long-Term Safety and Efficacy Study
|
Phase 4 | |
Completed |
NCT02250157 -
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT05566574 -
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03943004 -
Trial of DFP-14927 in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06036836 -
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
|
Phase 2 | |
Recruiting |
NCT05525858 -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
|
||
Recruiting |
NCT05798546 -
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
|
Phase 1 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT00479128 -
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04143789 -
Evaluation of AP-002 in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 |